The strong upward momentum in Vaxcyte shares is primarily driven by groundbreaking clinical trial data for its lead vaccine candidate, VAX-31, alongside a wave of bullish Wall Street research coverage. The company recently released pivotal Phase 3 OPUS-1 trial results evaluating its 31-valent pneumococcal conjugate vaccine candidate in adults. The candidate met all primary immunogenicity, immunobridging, and safety endpoints when benchmarked against existing standard-of-care treatments from major pharmaceutical competitors. By exceeding market expectations across multiple age groups and demonstrating a safety profile consistent with existing standard vaccines, VAX-31 reinforced its position as a potential best-in-class asset in a…